Year All20242023202220212020201920182017201620152014 May 02, 2024 Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock May 02, 2024 Soleno Therapeutics Announces Proposed Public Offering of Common Stock Apr 30, 2024 Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome Apr 29, 2024 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) Apr 19, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 08, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results Feb 22, 2024 Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference Feb 01, 2024 Soleno Therapeutics to Present at Upcoming February Investor Conferences Jan 29, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024 Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
Apr 30, 2024 Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
Apr 29, 2024 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
Mar 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results